MX2007004506A - Antiviral oligonucleotides. - Google Patents

Antiviral oligonucleotides.

Info

Publication number
MX2007004506A
MX2007004506A MX2007004506A MX2007004506A MX2007004506A MX 2007004506 A MX2007004506 A MX 2007004506A MX 2007004506 A MX2007004506 A MX 2007004506A MX 2007004506 A MX2007004506 A MX 2007004506A MX 2007004506 A MX2007004506 A MX 2007004506A
Authority
MX
Mexico
Prior art keywords
animal
human
treatment
oligonucleotides
prophylaxis
Prior art date
Application number
MX2007004506A
Other languages
Spanish (es)
Inventor
Andrew Vaillant
Jean-Marc Juteau
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/969,812 external-priority patent/US20050196382A1/en
Application filed by Replicor Inc filed Critical Replicor Inc
Priority claimed from PCT/CA2005/001623 external-priority patent/WO2006042418A1/en
Publication of MX2007004506A publication Critical patent/MX2007004506A/en

Links

Abstract

Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length and include chemical modifications, such as modified internucleotidic linkages and modifications at the 2'-position of the ribose moieties. Also described are uses for the prophylaxis or treatment of a viral infection in a human or animal, and use for the prophylaxis or treatment of cancer caused by oncoviruses in a human or animal. The uses typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least one oligonucleotide that act by a sequence independent mode of action.
MX2007004506A 2004-10-19 2005-10-19 Antiviral oligonucleotides. MX2007004506A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/969,812 US20050196382A1 (en) 2002-09-13 2004-10-19 Antiviral oligonucleotides targeting viral families
US66898305P 2005-04-07 2005-04-07
PCT/CA2005/001623 WO2006042418A1 (en) 2004-10-19 2005-10-19 Antiviral oligonucleotides

Publications (1)

Publication Number Publication Date
MX2007004506A true MX2007004506A (en) 2007-06-13

Family

ID=40273415

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004506A MX2007004506A (en) 2004-10-19 2005-10-19 Antiviral oligonucleotides.

Country Status (2)

Country Link
IL (1) IL182671A0 (en)
MX (1) MX2007004506A (en)

Also Published As

Publication number Publication date
IL182671A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
MXPA05002791A (en) Non-sequence complementary antiviral oligonucleotides.
AP1893A (en) Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof
MY144616A (en) Substituted dihydroquinazolines
NZ522326A (en) Adenosine A2A receptor antagonists
WO2002043652A3 (en) Anti-proliferative drugs
WO2001039777A8 (en) Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
NZ601544A (en) Combination therapy for the treatment of ocular neovascular disorders
CO6241169A2 (en) METHODS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
BR0308429A (en) Monocyclic Aroylpyridinones as Anti-Inflammatory Agents
EP2023940A4 (en) Compounds and methods for modulating expression of sglt2
UY26981A1 (en) METALOPROTEINASE INHIBITORS OF THE PYRIMIDIN-2,4,6-TRIONA TYPE
NO20054861L (en) Antigen oligonucleotides (ODN) against SMAD7 and uses thereof in the medical field
WO2005051429A3 (en) Targeted conjugates with a modified saccharide linker
BRPI0509927A (en) pharmaceutical composition, use of a composition of matter, and use of a therapeutically effective combination of a survivin antisense oligonucleotide and gemcitabine hydrochloride
MX2007004882A (en) Xanthine derivatives with hm74a receptor activity.
MXPA05011208A (en) Topical formulation of ivermectin for the treatment of dermatological conditions.
CY1108165T1 (en) LOCAL USE OF NF-κB BATTERY FOR THE TREATMENT OF TREATMENT OF ATOPHIC SKIN
ITMI20041550A1 (en) USE OF PROBIOTIC BACTERIA FOR THE PREPARATION OF TOPICAL COMPOSITIONS FOR THE PROTECTION OF THE EPIDERMIS
RU2008125041A (en) siRNA AGAINST MYOSIN VA AND DEPIGMENTATION OF SKIN
AR023966A1 (en) A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF PARKINSON'S DISEASE AND THE CONCOMITING SYMPTOMS OF THE SAME, AND THE USE OF A DUAL ADENOSINE A1 A2A RECEIVER UNANTAGONIST TO PREPARE SUCH COMPOSITION
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
MXPA04005156A (en) Adenosine a2a.
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
GB9902555D0 (en) Medicament
DE69500618D1 (en) OLIGONUCLEOTIDES WITH EFFECT AGAINST THE RESPIRATORY SYNCYTIAL VIRUS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal